Evolutec Group PLC
27 February 2006
For immediate release 27 February 2006
EVOLUTEC GROUP PLC
('Evolutec' or 'Company')
POSITIVE PHARMACOKINETIC PROFILE FOR rEV131
Further details in analyst briefing and webcast of Evolutec's results for the
year ended 31 December 2005 to be announced on 28 February 2006
Evolutec Group plc (AIM: EVC), the biopharmaceutical company developing novel
products for the treatment of allergic, inflammatory and autoimmune diseases, is
pleased to announce a positive preclinical metabolic result for its lead
molecule, rEV131.
This study demonstrates that rEV131 has a favourable pharmacokinetic profile
including:
• a circulating half-life of approximately 8 hours;
• uniform tissue distribution; and
• 95 per cent clearance from the body via the renal route within 24 hours.
This profile is well suited for a drug intended for use once or twice a day in
indications such as allergic rhinitis (hay fever) and asthma. Furthermore, the
trial showed that rEV131 does not cross the blood brain barrier, reducing the
possibility of unwanted effects such as drowsiness.
Mark Carnegie Brown, Evolutec's Chief Executive Officer, commented: 'This result
underpins the potential of rEV131, our lead drug product candidate. It also
endorses Evolutec's technology and approach, which is based around proteins
sourced from the saliva of ticks.'
Further details will be included in a briefing tomorrow for analysts on
Evolutec's 2005 results, which will be held at 10.30am (28 February 2006) at the
offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.
The briefing will also be webcast live. To connect to the webcast, please go to
the Company's website: http://www.evolutec.co.uk approximately 10 minutes
(10.20am) before the start of the briefing. The webcast will also be available
for replay shortly after the presentation.
ENDS
For further information:
Evolutec 0118 922 4480
Mark Carnegie Brown, Chief Executive Officer
Nicholas Badman, Chief Financial Officer
www.evolutec.co.uk
Buchanan Communications 020 7466 5000
Mark Court/Tim Anderson/Mary-Jane Johnson
Notes for Editors:
About Evolutec
Evolutec is a biopharmaceutical company developing drugs for allergy,
inflammation and autoimmune disease.
Evolutec's lead drug candidate, rEV131 has efficacy in both acute and chronic
respiratory indications including allergic rhinitis (hay fever) and asthma. In
2005, Evolutec announced a positive result for rEV131 in a 112 patient Phase IIa
proof of concept study in allergic rhinitis. rEV131 met the primary efficacy
endpoint (p < 0.05). In addition, rEV131 showed efficacy against mucus and
congestion, the most difficult to treat symptoms of rhinitis as well as a rapid
onset of action.
Evolutec intends to carry out additional proof of concept Phase II trials with
rEV131 in post-cataract surgery and dry eye. Positive preclinical data has also
been generated in asthma. rEV131 is a histamine binding protein and is
understood to be the only product currently in clinical trials that impacts the
recently discovered H4 receptor, a receptor implicated in many forms of
inflammatory disease.
The Company has a further two molecules in preclinical development. rEV576, a
complement inhibitor that was very effective in a preclinical model of
myasthenia gravis, and rEV598, which is being evaluated in carcinoid syndrome
and CINV (chemotherapy-induced nausea and vomiting). Evolutec is working with
Merial to develop anti-tick and anti-tick borne disease vaccines.
Evolutec, which is based in Reading, UK, was founded in 1998 to exploit research
carried out by the Natural Environment Research Council. Evolutec's drugs were
first isolated from the saliva of ticks but are now manufactured by bacterial
fermentation procedures. The tick remains undetected by its hosts, including
humans, by injecting an array of molecules into the skin that suppresses normal
defence mechanisms. These stealth molecules have evolved over millions of years
to enable the tick to take a blood meal from its host. Evolutec employs the
tick's evolutionary stealth technology to offer the potential of treating human
diseases.
Safe Harbour statement: this news release may contain forward-looking statements
that reflect the current expectations of the Company regarding future events.
Forward-looking statements involve risks and uncertainties. Actual events could
differ materially from those projected herein and depend on a number of factors
including the success of the Company's research strategies, the applicability of
the discoveries made therein, the successful and timely completion of clinical
studies, the uncertainties related to the regulatory process, the successful
integration of completed mergers and acquisitions and achievement of expected
synergies from such transactions, and the ability of the Company to identify and
consummate suitable strategic and business combination transactions.
This information is provided by RNS
The company news service from the London Stock Exchange
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.